Inhibition of translocator protein 18 kDa suppressed the progression of glioma via the ELAV-like RNA-binding protein 1/MAPK-activated protein kinase 3 axis
Glioma is the most common primary malignant brain tumors in adults. Despite considerable advances in treatment, the clinical outcome remains dismal. Translocator protein 18 kDa (TSPO), an evolutionarily conserved transmembrane protein, has always been found to be elevated in glioma, which predicts a...
Saved in:
Published in | Bioengineered Vol. 13; no. 3; pp. 7457 - 7470 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Taylor & Francis
01.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Glioma is the most common primary malignant brain tumors in adults. Despite considerable advances in treatment, the clinical outcome remains dismal. Translocator protein 18 kDa (TSPO), an evolutionarily conserved transmembrane protein, has always been found to be elevated in glioma, which predicts a poor prognosis. However, studies on the regulatory network of TSPO in glioma are limited. The Cancer Genome Atlas (TCGA) and our research group cohorts demonstrated that TSPO expression was also highly expressed in glioma tissues and glioma cell lines. Inhibition of TSPO expression significantly reduced glioma cell proliferation and mobility in vitro. Suppression of TSPO decreased the expression of MAPK-activated protein kinase 3 (MAPKAPK3) and increased the degradation rate of its mRNA. TSPO directly interacts with ELAV1-like RNA-binding protein 1 (HUR) and promotes the nuclear-cytoplasmic shuttling of HUR. Inhibition of HUR decreased MAPKAPK3 expression and cell proliferation and mobility, whereas overexpression of MAPKAPK3 reversed the effects. Overexpression of HUR in TSPO-knockdown cells enhanced the mRNA stability of MAPKAPK3. Furthermore, rescue experiments show that the HUR/MAPKAPK3 axis accounts for the TSPO-mediated effects on glioma cell proliferation and mobility. Together, our present study indicated that TSPO may promote the nuclear-cytoplasmic shuttling of HUR, thus increasing the mRNA stability of MAPKAPK3 and promoting the proliferation and mobility of glioma cells. The HUR/MAPKAPK3 axis may be key targets for blocking the effects of TSPO and may contribute to glioma therapy. |
---|---|
AbstractList | Glioma is the most common primary malignant brain tumors in adults. Despite considerable advances in treatment, the clinical outcome remains dismal. Translocator protein 18 kDa (TSPO), an evolutionarily conserved transmembrane protein, has always been found to be elevated in glioma, which predicts a poor prognosis. However, studies on the regulatory network of TSPO in glioma are limited. The Cancer Genome Atlas (TCGA) and our research group cohorts demonstrated that TSPO expression was also highly expressed in glioma tissues and glioma cell lines. Inhibition of TSPO expression significantly reduced glioma cell proliferation and mobility in vitro. Suppression of TSPO decreased the expression of MAPK-activated protein kinase 3 (MAPKAPK3) and increased the degradation rate of its mRNA. TSPO directly interacts with ELAV1-like RNA-binding protein 1 (HUR) and promotes the nuclear-cytoplasmic shuttling of HUR. Inhibition of HUR decreased MAPKAPK3 expression and cell proliferation and mobility, whereas overexpression of MAPKAPK3 reversed the effects. Overexpression of HUR in TSPO-knockdown cells enhanced the mRNA stability of MAPKAPK3. Furthermore, rescue experiments show that the HUR/MAPKAPK3 axis accounts for the TSPO-mediated effects on glioma cell proliferation and mobility. Together, our present study indicated that TSPO may promote the nuclear-cytoplasmic shuttling of HUR, thus increasing the mRNA stability of MAPKAPK3 and promoting the proliferation and mobility of glioma cells. The HUR/MAPKAPK3 axis may be key targets for blocking the effects of TSPO and may contribute to glioma therapy. Glioma is the most common primary malignant brain tumors in adults. Despite considerable advances in treatment, the clinical outcome remains dismal. Translocator protein 18 kDa (TSPO), an evolutionarily conserved transmembrane protein, has always been found to be elevated in glioma, which predicts a poor prognosis. However, studies on the regulatory network of TSPO in glioma are limited. The Cancer Genome Atlas (TCGA) and our research group cohorts demonstrated that TSPO expression was also highly expressed in glioma tissues and glioma cell lines. Inhibition of TSPO expression significantly reduced glioma cell proliferation and mobility . Suppression of TSPO decreased the expression of MAPK-activated protein kinase 3 (MAPKAPK3) and increased the degradation rate of its mRNA. TSPO directly interacts with ELAV1-like RNA-binding protein 1 (HUR) and promotes the nuclear-cytoplasmic shuttling of HUR. Inhibition of HUR decreased MAPKAPK3 expression and cell proliferation and mobility, whereas overexpression of MAPKAPK3 reversed the effects. Overexpression of HUR in TSPO-knockdown cells enhanced the mRNA stability of MAPKAPK3. Furthermore, rescue experiments show that the HUR/MAPKAPK3 axis accounts for the TSPO-mediated effects on glioma cell proliferation and mobility. Together, our present study indicated that TSPO may promote the nuclear-cytoplasmic shuttling of HUR, thus increasing the mRNA stability of MAPKAPK3 and promoting the proliferation and mobility of glioma cells. The HUR/MAPKAPK3 axis may be key targets for blocking the effects of TSPO and may contribute to glioma therapy. Glioma is the most common primary malignant brain tumors in adults. Despite considerable advances in treatment, the clinical outcome remains dismal. Translocator protein 18 kDa (TSPO), an evolutionarily conserved transmembrane protein, has always been found to be elevated in glioma, which predicts a poor prognosis. However, studies on the regulatory network of TSPO in glioma are limited. The Cancer Genome Atlas (TCGA) and our research group cohorts demonstrated that TSPO expression was also highly expressed in glioma tissues and glioma cell lines. Inhibition of TSPO expression significantly reduced glioma cell proliferation and mobility in vitro . Suppression of TSPO decreased the expression of MAPK-activated protein kinase 3 (MAPKAPK3) and increased the degradation rate of its mRNA. TSPO directly interacts with ELAV1-like RNA-binding protein 1 (HUR) and promotes the nuclear–cytoplasmic shuttling of HUR. Inhibition of HUR decreased MAPKAPK3 expression and cell proliferation and mobility, whereas overexpression of MAPKAPK3 reversed the effects. Overexpression of HUR in TSPO-knockdown cells enhanced the mRNA stability of MAPKAPK3. Furthermore, rescue experiments show that the HUR/MAPKAPK3 axis accounts for the TSPO-mediated effects on glioma cell proliferation and mobility. Together, our present study indicated that TSPO may promote the nuclear–cytoplasmic shuttling of HUR, thus increasing the mRNA stability of MAPKAPK3 and promoting the proliferation and mobility of glioma cells. The HUR/MAPKAPK3 axis may be key targets for blocking the effects of TSPO and may contribute to glioma therapy. |
Author | Ren, Peng Zeng, Zhirui Ma, Li Zhang, Hongmei Wang, Jingya Guo, Wenzhi Li, Yunjun |
Author_xml | – sequence: 1 givenname: Jingya surname: Wang fullname: Wang, Jingya organization: School of Basic Medical Sciences, Guizhou Medical University – sequence: 2 givenname: Peng orcidid: 0000-0002-4643-4926 surname: Ren fullname: Ren, Peng organization: The Seventh Medical Center of Chinese PLA General Hospital – sequence: 3 givenname: Zhirui surname: Zeng fullname: Zeng, Zhirui organization: School of Basic Medical Sciences, Guizhou Medical University – sequence: 4 givenname: Li surname: Ma fullname: Ma, Li organization: The Seventh Medical Center of Chinese PLA General Hospital – sequence: 5 givenname: Yunjun surname: Li fullname: Li, Yunjun organization: The Seventh Medical Center of Chinese PLA General Hospital – sequence: 6 givenname: Hongmei orcidid: 0000-0002-4177-1448 surname: Zhang fullname: Zhang, Hongmei email: 249402604@qq.com organization: The Affiliated Hospital of Weifang Medical University – sequence: 7 givenname: Wenzhi surname: Guo fullname: Guo, Wenzhi email: elite2005gg@163.com organization: The Seventh Medical Center of Chinese PLA General Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35285415$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1yFCEUhSkrKRNjHkGLpZtO-Gka2FhOxWhSTtSy1C1F0_QMTje0wIzmWXzZdDs_6sYNcDnnnkvxPQFHPngLwDOMLjAS6JLgijHJ5QVBhIxLKaQkj8DpdF8wKfjR4czlCThP6RtCCCNaMi4egxPKiGAlZqfg161futplFzwMLcxR-9QFo3OIcIghW-chFnD1WsO0HoZoU7INzEs7qYup3HUuOhd6DTdO_1av57OvRedWFn56Pytq5xvnF38SL-9mH98V2mS30XkM3Asr53WykEL906Wn4LjVXbLnu_0MfHlz_fnqpph_eHt7NZsXhtEyFxSJsqG4MbSt2opyVHPEjJWGNFrYWhLNhKHMUC0qjY2hnErMK9SWvGk4RfQMvNzmDuu6t42xfvyGTg3R9Treq6Cd-lfxbqkWYaMkQYJROga82AXE8H1tU1a9S8Z2nfY2rJMiFRWyxBiT0cq2VhNDStG2hzEYqYmt2rNVE1u1Yzv2Pf_7jYeuPcnR8GprcL4Nsdc_QuwalfV9F2I7UjUuKfr_GQ9SCrce |
CitedBy_id | crossref_primary_10_3389_fgene_2022_976356 crossref_primary_10_1021_acs_molpharmaceut_2c01069 crossref_primary_10_1126_sciadv_adi8986 |
Cites_doi | 10.1007/s13402-021-00609-w 10.1007/s00018-008-8252-6 10.1016/S0896-6273(00)80395-5 10.1016/j.bbr.2017.01.025 10.1007/s11064-020-03036-9 10.1016/j.biopha.2017.09.086 10.7554/eLife.05289 10.1182/blood-2011-01-329300 10.1016/j.tips.2006.06.005 10.1016/j.bbadis.2007.12.001 10.1016/j.jphs.2020.10.004 10.1080/15384047.2019.1591673 10.3390/cancers12102973 10.1186/s12943-017-0624-9 10.1128/MCB.00410-15 10.2741/3921 10.7150/thno.40076 10.1016/j.biocel.2017.05.022 10.1007/978-3-030-19966-1_2 10.3390/ijms18040786 10.1016/S0304-3835(03)00052-1 10.1002/jnr.23687 10.1038/oncsis.2014.21 10.3389/fonc.2021.636632 10.2174/138161207781368710 10.2174/1568009618666181031145953 10.2967/jnumed.110.086629 10.1007/s00259-021-05276-5 10.1073/pnas.97.12.6242 10.1128/MCB.22.10.3425-3436.2002 10.1038/s41401-019-0293-x 10.2174/1871520614666140309230338 10.1016/j.bbamcr.2006.10.001 10.3390/ijms21020612 10.1080/21655979.2021.1943986 10.1098/rstb.2006.1894 |
ContentType | Journal Article |
Copyright | 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
Copyright_xml | – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
DBID | 0YH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1080/21655979.2022.2048992 |
DatabaseName | Taylor & Francis Open Access Journals Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access Journals url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
DocumentTitleAlternate | J. WANG ET AL |
EISSN | 2165-5987 |
EndPage | 7470 |
ExternalDocumentID | 10_1080_21655979_2022_2048992 35285415 2048992 |
Genre | Research Paper Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 0YH 4.4 53G AAAVI ABCCY ABPEM ACGFS ADBBV ADCVX AENEX AHDLD AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV DGEBU EBS EMOBN FUNRP FVPDL GROUPED_DOAJ GTTXZ IPNFZ M4Z OK1 RIG RPM SV3 TFL TFW V1K CGR CUY CVF ECM EIF EJD H13 HYE NPM OVD TDBHL TEORI TTHFI AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c534t-3084d31dc3f6f6370b705ce9c2da8eb92a58c35c3a86a1cc37391760f47dd7303 |
IEDL.DBID | RPM |
ISSN | 2165-5979 |
IngestDate | Tue Sep 17 21:13:32 EDT 2024 Fri Aug 16 21:21:15 EDT 2024 Fri Aug 23 02:39:19 EDT 2024 Tue Aug 27 13:48:24 EDT 2024 Tue Jun 13 19:24:28 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | TSPO mobility Glioma HUR MAPKAPK3 proliferation |
Language | English |
License | open-access: http://creativecommons.org/licenses/by/4.0/: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c534t-3084d31dc3f6f6370b705ce9c2da8eb92a58c35c3a86a1cc37391760f47dd7303 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
ORCID | 0000-0002-4177-1448 0000-0002-4643-4926 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208533/ |
PMID | 35285415 |
PQID | 2638941112 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | crossref_primary_10_1080_21655979_2022_2048992 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9208533 informaworld_taylorfrancis_310_1080_21655979_2022_2048992 proquest_miscellaneous_2638941112 pubmed_primary_35285415 |
PublicationCentury | 2000 |
PublicationDate | 2022-03-01 |
PublicationDateYYYYMMDD | 2022-03-01 |
PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Bioengineered |
PublicationTitleAlternate | Bioengineered |
PublicationYear | 2022 |
Publisher | Taylor & Francis |
Publisher_xml | – name: Taylor & Francis |
References | cit0011 cit0033 cit0012 cit0034 cit0031 cit0010 cit0032 cit0030 Guo Y-J (cit0017) 2020; 19 cit0019 cit0018 cit0015 cit0037 cit0016 cit0013 cit0035 cit0014 cit0036 cit0022 cit0001 cit0023 cit0020 cit0021 cit0008 cit0009 cit0006 cit0028 cit0007 cit0029 cit0004 cit0026 cit0005 cit0027 cit0002 cit0024 cit0003 cit0025 |
References_xml | – ident: cit0001 doi: 10.1007/s13402-021-00609-w – ident: cit0012 doi: 10.1007/s00018-008-8252-6 – ident: cit0029 doi: 10.1016/S0896-6273(00)80395-5 – ident: cit0035 doi: 10.1016/j.bbr.2017.01.025 – ident: cit0006 doi: 10.1007/s11064-020-03036-9 – ident: cit0032 doi: 10.1016/j.biopha.2017.09.086 – ident: cit0018 doi: 10.7554/eLife.05289 – ident: cit0007 doi: 10.1182/blood-2011-01-329300 – ident: cit0005 doi: 10.1016/j.tips.2006.06.005 – ident: cit0026 doi: 10.1016/j.bbadis.2007.12.001 – ident: cit0027 doi: 10.1016/j.jphs.2020.10.004 – ident: cit0014 doi: 10.1080/15384047.2019.1591673 – ident: cit0025 doi: 10.3390/cancers12102973 – ident: cit0022 doi: 10.1186/s12943-017-0624-9 – ident: cit0015 doi: 10.1128/MCB.00410-15 – ident: cit0037 doi: 10.2741/3921 – ident: cit0019 doi: 10.7150/thno.40076 – ident: cit0023 doi: 10.1016/j.biocel.2017.05.022 – ident: cit0016 doi: 10.1007/978-3-030-19966-1_2 – ident: cit0010 doi: 10.3390/ijms18040786 – ident: cit0033 doi: 10.1016/S0304-3835(03)00052-1 – ident: cit0020 doi: 10.1002/jnr.23687 – ident: cit0021 doi: 10.1038/oncsis.2014.21 – volume: 19 start-page: 1997 issue: 3 year: 2020 ident: cit0017 publication-title: Exp Ther Med contributor: fullname: Guo Y-J – ident: cit0030 doi: 10.3389/fonc.2021.636632 – ident: cit0011 doi: 10.2174/138161207781368710 – ident: cit0036 doi: 10.2174/1568009618666181031145953 – ident: cit0008 doi: 10.2967/jnumed.110.086629 – ident: cit0024 doi: 10.1007/s00259-021-05276-5 – ident: cit0003 doi: 10.1073/pnas.97.12.6242 – ident: cit0013 doi: 10.1128/MCB.22.10.3425-3436.2002 – ident: cit0034 doi: 10.1038/s41401-019-0293-x – ident: cit0004 doi: 10.2174/1871520614666140309230338 – ident: cit0031 doi: 10.1016/j.bbamcr.2006.10.001 – ident: cit0009 doi: 10.3390/ijms21020612 – ident: cit0002 doi: 10.1080/21655979.2021.1943986 – ident: cit0028 doi: 10.1098/rstb.2006.1894 |
SSID | ssj0001034578 |
Score | 2.2935688 |
Snippet | Glioma is the most common primary malignant brain tumors in adults. Despite considerable advances in treatment, the clinical outcome remains dismal.... |
SourceID | pubmedcentral proquest crossref pubmed informaworld |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 7457 |
SubjectTerms | Adult Cell Line, Tumor ELAV-Like Protein 1 - genetics ELAV-Like Protein 1 - metabolism Gene Expression Regulation, Neoplastic Glioma Glioma - metabolism Humans HUR MAPKAPK3 mobility proliferation Protein Kinases - genetics Protein Kinases - metabolism Protein Kinases - therapeutic use Receptors, GABA - genetics Receptors, GABA - metabolism Receptors, GABA - therapeutic use Research Paper RNA-Binding Proteins - metabolism TSPO |
SummonAdditionalLinks | – databaseName: Taylor & Francis Open Access Journals dbid: 0YH link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQucAB8WZ5yUhcTR2PnTjHFbRaHq0QoghOkV-h0ZZsRbIV_4U_i8dJtrsIxIFjZI9laeyZb5zPnwl5LrQ2ICxnVmpg0jvOtFSK1c5jOlS2cHgOeXScL07km89qYhN2I60Sa-h6EIpIsRo3t7HdxIjbF1mOOBivmQi8SyVjzRCj8FURoTey-viXxeUxCwepUjxGK4Zm0z2ev420k6F29Ev_hEJ_J1NuZafDm-TGCCvpfFgHt8iV0N4m17fEBu-Qn6_b08YmhhZd1bTHJIWZLBbdNKk1NC3NNF2-MrRbnyd-bPA04kOaOFyDfgdafj1rVt8MvWhMaj14N__EzpploB-O51hoYza8HHH_aP7-LcPrExcR1vpNw7JpYwKlQM2PprtLTg4PPr5csPFpBuYUyJ4B19JD5h3UeZ1DwW3BlQulE97oYEthlHagHBidm8w5KCDWhTmvZeF9DCpwj-y1qzY8IDQvffBWlco7J2PnMhaB0nBhYmWpSs9n5MXkjup8UOCoslHYdPJfhf6rRv_NSLnttKpPRx_18E5JBf-wfTZ5uIr7DH-emDas1l0lENrJmBlin_uDxzfTQYUcFZHQjBQ7a2HTATW8d1va5jRpeZf4RirAw_-Y8yNyDT8HYtxjstd_X4cnESn19mnaC78ADC4J_A priority: 102 providerName: Taylor & Francis |
Title | Inhibition of translocator protein 18 kDa suppressed the progression of glioma via the ELAV-like RNA-binding protein 1/MAPK-activated protein kinase 3 axis |
URI | https://www.tandfonline.com/doi/abs/10.1080/21655979.2022.2048992 https://www.ncbi.nlm.nih.gov/pubmed/35285415 https://search.proquest.com/docview/2638941112 https://pubmed.ncbi.nlm.nih.gov/PMC9208533 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa2e4ID4k15rIzE1Y2TsRPnWC27Ko-uVohFyyly7ISN2qYVTVf8F_4sHicpKUJC4hrbkaMZ-5vPGX9DyJtIKQ1RzlkuFDBhDWdKSMlKYxEOZZ4YPIecX8SzK_H-Wl4fEdnfhfFJ-yavJvVyNamrG59buVmZoM8TCy7npykWlgQIRmSUAAwouj9Y4SCk34GjMJbMBcxpf3NH8QCf4SPHDCO8hyUc38CKNihyIgUWxx3A04F46d9C0D8zKQfQdH6f3OtiSjpt5_6AHBX1Q3J3oDT4iPx8V99UuU_PouuSNohQCGOOcVMv1VDVNFR08VbT7W7jk2MLS11wSH0CVyvegSO_Lav1StPbSvvWs4_TL2xZLQr66WKKLBuh8Pcbg_n08gPDuxO3Lqa1-4ZFVTv0pED1j2r7mFydn30-nbGuLgMzEkTDgCthIbQGyriMIeF5wqUpUhNZrYo8jbRUBqQBrWIdGgMJOFIY81Ik1rodBZ6Q43pdF88IjVNb2Fym0hojXOfUMUCheaQdrZSp5WMy6c2RbVr5jSzsVE17U2Zoyqwz5ZikQ6NljT_3KNsiJRn8Y-zr3sKZW2T450TXxXq3zSKM64SDBdfnaWvx_XR6zxmT5MAX9h1QwPuwxfm1F_Lu_Pj5f498Qe7gB7Q5cS_JcfN9V7xyQVKTn5AR_zo78UvjF0yUDmQ |
link.rule.ids | 230,315,733,786,790,891,27535,27957,27958,53827,53829,59498,59499 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLa67mHbw-6X7OpJezUYbIN5jLpW6ZpE1dRWfUPGhhYlIdFCqml_ZX92PgYyUk2atldfEBaffc4x3_kOQp9CKRULM0oyLhnhRlMiuRCk0AbMochiDfeQk2k0OudfLsXlHhJdLowj7eus9Kr5wqvKa8etXC203_HE_NPJQQKFJRnz76C7dr-GcS9Id1crlHHhzuAwiASxLnPS5e5I6kMbNNnYMIRMLG4jDqhpAzIngkN53J6B2pEv_ZMTeptL2TNOR4_QRbeshpMy8zZ15ukftxQf_3ndj9HD1l3Fw6b7CdrLq6foQU_E8Bn6eVxdl5ljfuFlgWswfmAhbTCPnQpEWeFA4tlnhdeblePd5gZbvxM7blijCwIzr-blcqHwTalc7-F4eEHm5SzHX6dDCODByv5-oj8Znp4QSMu4se6y2XbMysoaZsyw-l6un6Pzo8OzgxFpSz4QLRivCaOSGxYYzYqoiFhMs5gKnSc6NErmWRIqITUTmikZqUBrFjMbb0a04LEx9rBiL9B-tazyVwhHiclNJhJhtOZ2cGKDS65oqGzEKhJDB8jrvnO6apQ90qAVTO0wkgJG0hYjA5T00ZDW7kqlaOqfpOwvcz920Ent_oWfMqrKl5t1GoLLyK3FsWNeNlDavk4HyQGKd0C2HQDa4Ls9FjpOI7yFyuv_nvkB3RudTcbp-Hh68gbdh8U01Lu3aL_-tsnfWV-szt67nfcLYosvaA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSAgeuMPK1Ui8OnFiO7Efq23VxtaqQgxNvES-JCxqm1ZrOiH-Cn8W20lKOiEh7dU-jmLls885zufvAPAp5lySWGGkKCeIGo0Rp4yhQhvnDplKtTuHHE-S43P6-YJd9Ep9edK-VmVQzRdBVV56buVqocOOJxZOxwfCFZYkJFyZIrwL7tk1G4teou6PVzChzO_DcZQwZMNm0d3f4Th0ba7J5oexu41Fbdbh6to4qRNGXYncnpPakTD9VyB6k0_Zc1Cjx-B7N7WGlzILNrUK9K8bqo-3mvsT8KgNW-GwMXkK7uTVM_CwJ2b4HPw-qS5L5RlgcFnA2jlB5yltUg-9GkRZwYjD2aGE683K829zA238CT1HrNEHcSN_zMvlQsLrUvreo7PhNzQvZzn8Mhm6RN55279PDMfD6Sly1zOubdhsth2zsrIOGhIof5brF-B8dPT14Bi1pR-QZoTWiGBODYmMJkVSJCTFKsVM50LHRvJciVgyrgnTRPJERlqTlNi8M8EFTY2xmxZ5CfaqZZXvA5gIkxvFBDNaU2ssbJJJJY6lzVyZMHgAgu5bZ6tG4SOLWuHUDieZw0nW4mQARB8RWe2PVoqmDkpG_jP2YwefzK5j93NGVvlys85iFzpS63mszasGTtvX6WA5AOkO0LYGTiN8t8fCx2uFt3B5feuRH8D96eEoOzuZnL4BD9xcGgbeW7BXX23ydzYkq9V7v_j-AO9fMeg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+translocator+protein+18+kDa+suppressed+the+progression+of+glioma+via+the+ELAV-like+RNA-binding+protein+1%2FMAPK-activated+protein+kinase+3+axis&rft.jtitle=Bioengineered&rft.au=Wang%2C+Jingya&rft.au=Ren%2C+Peng&rft.au=Zeng%2C+Zhirui&rft.au=Ma%2C+Li&rft.date=2022-03-01&rft.eissn=2165-5987&rft.volume=13&rft.issue=3&rft.spage=7457&rft_id=info:doi/10.1080%2F21655979.2022.2048992&rft_id=info%3Apmid%2F35285415&rft.externalDocID=35285415 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-5979&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-5979&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-5979&client=summon |